Company intelligence / Profile preview

Nirsum Laboratories

New York City, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Nirsum Laboratories is developing a small molecule opioid receptor antagonist for opioid use disorder, with its lead program in Phase 1 trials as of August 2025[4].

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

nalmefene prodrug

Beyond the preview

Go deeper on Nirsum Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nirsum Laboratories.

Explore the full profile